Science and Innovation Community (SIC) was set up to identify and build on evolving science trends in the biotech industry that can give the UK a competitive advantage.
The aims of the committee are to:
- Influence the policy of government and funders of UK science and technology through proactive engagement with key stakeholders to the benefit of UK life science companies in the post-pandemic funding environment
- Encourage active networking between BIA member companies to facilitate communication, collaboration and sharing of best practice for mutual benefit
- Address the identified science skills shortage in UK life sciences by exploring using the BIA MAC LeaP framework for skills development in the R&D community
- Support adoption of digital and AI technologies in Discovery Science
- Continue engagement with scientific and research communities and wider innovation ecosystem, UKRI and other funding bodies
- Increase number of SME members on the committee
- Cross committee engagement (guests for a future-gazing session)
- Support the BIA’s Comprehensive Spending Review activities
- Through active engagement with funders, influence relevant areas of science policy in the post-pandemic funding environment
- Design and deliver a Digital workshop/session following on from the 2021 event
- Bring forward proposals for ARIA competition should ARIA funding emerge
- Keep KTN Funding Map current through quarterly engagement with funding stakeholders
- Explore using the BIA MAC LeaP framework for skills development in the R&D community
BIA member benefits – why should you engage with SIC?
- A strong voice with key stakeholders in discovery and translational science
- Engagement with science funding bodies
- Connecting science for the cross-fertilisation of ideas
- Learn aboout and influence science policy
- Development of skills for the R&D community
- SIAC listens to member needs
SIC blogs and resources
Health Funding Map
Developed with KTN, this funding map helps in the navigation of the complicated world of innovation funding. The aim of the map is to provide an opportunity for innovators to start a conversation with KTN about how we can help you to navigate the innovation landscape.
New Science - Future Gazing
Every meeting one of the SIAC members volunteers to lead discussions around a piece of cutting-edge science. Peter Simpson, Chief Scientific Officer at the Medicines Discovery Catapult kicked off the first in the series entitled 'Smelling the disease: Nosing our way towards earlier diagnosis and new biomarkers'. In this blog, you will read about how 'super-smeller' Joy Milne can identify individuals with Parkinson's disease or giant rats in Tanzania can detect TB from sniffing sputum.
Shaping the future: What areas of science are most important to the UK bioindustry?
With the formation of UK Research and Innovation (UKRI) in April 2018 and the reorganisation of the UK’s science funding system, SIAC led a ‘Shaping the future’ workstream to identify areas of science that are most critical to the ongoing success of our industry. This paper summarises the conclusions and recommendations of the workstream and represents a snapshot of expert views from across the whole sector.
SIAC brought together representatives from across the biotech/healthcare community to discuss technology transfer. This followed the Dowling Report and the subsequent report by the House of Commons Science and Select Committee on managing academic intellectual property. The BIA intends to address some of the issues highlighted, such as friction around IP licencing, by bringing together all the relevant parties and encouraging open dialogue.
Accelerating Drug Discovery through digital and AI innovations
On 15 September 2021, SIAC hosted a workshop designed to engage UK industrial users of data, provide an overview of the use of Data/AI in drug discovery, and capture present and future industry needs and challenges regarding the development and use of data analytics and data systems.
Chaired by Justin Bryans, Vice-Chair of SIAC, there were short presentations on data generation, access, application, manipulation and visualisation from Dan Jamieson (Biorelate), Richard Goodwin (AstraZeneca), Rafael Jimenez (Medicines Discovery Catapult) and Namshik Han (Milner Institute).
This was followed by a lively Q&A panel, where Adam Sardar (e-therapeutics) and Richard Smith (Healx) joined the speakers on the virtual stage, along with Karen Wilkinson (KTN) and Liliya Serazetdinova (Earlham Institute), who facilitated further discussions around the perceived barriers and challenges in the data and AI space. This well-attended workshop was the first SIAC event in this space, with follow-on topics identified during the event included in the programme of the BIA’s inaugural TechBioUK conference.
One of SIC's roles is to input into relevant consultations including: